Sign Up to like & get
recommendations!
1
Published in 2023 at "Cancer medicine"
DOI: 10.1002/cam4.6190
Abstract: BACKGROUND Extramammary Paget's disease (EMPD) is rare. There are no standard treatments due to its rarity and few clinical trials. METHODS The objective of this multicenter study was to investigate treatment outcomes of Korean patients…
read more here.
Keywords:
taxane;
treatment;
advanced metastatic;
chemotherapy ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2021 at "Pancreas"
DOI: 10.1097/mpa.0000000000001794
Abstract: Objectives Checkpoint inhibitors (CPIs) for low- and intermediate-grade neuroendocrine tumors (NETs) have been associated with limited efficacy; recent studies suggest CPIs may represent promising treatment for high-grade neuroendocrine neoplasms (NENs). Methods We examined 57 patients…
read more here.
Keywords:
patients poorly;
checkpoint inhibitors;
efficacy;
neuroendocrine neoplasms ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2021 at "Annals of palliative medicine"
DOI: 10.21037/apm-19-362
Abstract: BACKGROUND The purpose of this case series is to assess the safety and efficacy, as well as the overall survival (OS) and progression free survival (PFS) of patients with intrahepatic cholangiocarcinoma (ICC) treated with percutaneous…
read more here.
Keywords:
pfs months;
tace;
remain alive;
ablation ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2023 at "AntiCancer Research"
DOI: 10.21873/anticanres.16432
Abstract: Background/Aim: In the latest 2021 WHO classification of central nervous system tumours (CNS), gliomas that present isocitrate dehydrogenase (IDH) mutations are defined as diffuse low-grade gliomas (DLGGs). IDH mutations are commonly observed in this tumour…
read more here.
Keywords:
pfs months;
19q codeletion;
codeletion;
resection ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2021 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2021.654020
Abstract: Background Hepatocellular carcinoma (HCC) is the third most fatal cancer, with a 5-year survival rate of 18%. Standard frontline-therapy is multikinase inhibitors (MKIs), but accessibility is still limited, particularly in developing countries. This network meta-analysis…
read more here.
Keywords:
hepatocellular carcinoma;
pfs months;
median pfs;
multikinase inhibitors ... See more keywords